Prostate Cancer Treatment Platform

Emer Leahy, Ph.D., is the Chief Executive Officer of PsychoGenics Inc., bringing over 30 years of leadership experience in drug discovery, clinical development, and business strategy within the pharmaceutical and biotechnology industries. She holds a Ph.D. in neuropharmacology from University College Dublin, Ireland, and an MBA from Columbia University. Dr. Leahy has spearheaded innovative approaches to CNS drug discovery and development, and she also serves as an adjunct associate professor of neuroscience at Mount Sinai School of Medicine, contributing to academic research and mentorship in health matters.

Dr. Leahy’s expertise encompasses technology assessment, licensing, mergers and acquisitions, and strategic planning. Her governance experience includes service on the Emerging Companies Section Governing Board of the Biotechnology Industry Organization (BIO), the board of directors of New York Bio, the Business Review Board of the Alzheimer’s Drug Discovery Foundation, and the Scientific Advisory Board of the International Rett Syndrome Foundation.

Currently, Dr. Leahy serves on the boards of PsychoGenics Inc., Intensity Therapeutics—a clinical-stage oncology company—and Pasithea Therapeutics, a public company focused on brain disorder treatments. Additionally, she chairs BioNJ, the leading trade association for New Jersey’s life sciences sector. For more information or if you would like to contact us, please reach out.